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Purpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine 
are reviewed.
Summary: Azacitidine is the first drug FDA-approved for the treatment of   myelodysplastic 
  syndromes that has demonstrated improvements in overall survival and delaying time to 
  progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 
75 mg/m2 daily for 7 days, with different treatment schedules validated. It appears to be well 
tolerated, with the most common adverse effects being myelosuppression. Several other   off-label 
  recommendations were also analyzed.
Conclusion: Azacitidine is the first DNA hypomethylating agent approved by FDA for the 
treatment of myelodysplastic syndromes with demonstrated efficacy.
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Hypomethylating agents are a group of chemotherapeutic drugs with the capacity to 
induce transient DNA hypomethylation, an important mechanism in the treatment of 
myelodysplastic syndromes (MDS). Two hypomethylating agents approved in the 
United States and widely used in Europe and the rest of the world are azacitidine 
(5-azacytidine) and decitabine. Azacitidine has been reported to prolong survival 
in MDS patients. Azacitidine has been studied in different dosing schedules and 
  combination therapies with the objective of improving the response rates in patients 
with MDS and acute myelogenous leukemia (AML).
Azacitidine is a nucleoside analog with a ribose structure that is incorporated 
into RNA and requires the activity of ribonucleotide reductase to be incorporated to 
DNA.1 Azacitidine is phosphorylated intracellularly to its active form, azacitidine 
triphosphate.2,3 Like most nucleoside analogs, azacitidine enters cells using the nucleo-
side transporters hENT1 and hENT2, but unlike the nucleoside analog decitabine, 
azacitidine does not require deoxycytidine kinase for phosphorylation.
Uridine-cytidine kinase phosphorylates azacitidine to its active form.4 Because 
hypermethylation of the promoters of certain tumor suppression genes is prevalent in 
MDS and secondary AML, it is postulated that the DNA hypomethylation induced 
by azacitidine, may result in the reactivation of silenced genes, restoring their cancer-
suppressing functions, and inducing cellular differentiation.
Efficacy
Azacitidine as a front-line single agent
In the late 1960s and early 1970s, azacitidine was tested in a series of phase I and II trials 
as a classic cytotoxic agent and was found to be effective for the treatment of myeloid Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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malignancies. In these studies, most of them   involving 
patients with relapsed AML, azacitidine was mainly used 
in combinations and was administered at doses ranging 
from 100–750 mg/m2 with response rates ranging from 0% 
to 58%.4–8 In a phase I trial in which patients with relapsed 
leukemia received azacitidine intravenously at various sched-
ules at doses ranging from 150–750 mg/m2, higher remission 
rates were observed in patients treated with the lower doses.5 
Later studies performed by Cancer and Leukemia Group B 
(CALGB) demonstrated that azacitidine had activity in MDS 
and AML when given at 75 mg/m2 by intravenous infusion 
(CALGB 8421) or subcutaneous injection (CALGB 8921 
and 9221) daily for 7 days in a 28-day cycle.9–11 The cross-
over phase III CALGB 9221 trial10,11 showed a significant 
effect of azacitidine on response rates (P , 0.0001), with an 
overall response rate of 60% in patients receiving azacitidine 
compared with 5% in those receiving only supportive care. 
Patients who crossed over from supportive care to azacitidine 
had an overall response rate of 47%, confirming that azac-
itidine improved overall response. Although the difference 
was not significant (due to the crossover design of the study), 
there was a marked improvement in overall survival times 
for patients receiving azacitidine (20 months) compared with 
patients receiving supportive care (14 months). These data 
are summarized in Table 1. The CALGB 9221study results 
led to the approval of azacitidine in the United States for 
patients with MDS.
In a second randomized phase II study (AZA-001) 
  performed to determine the effect of azacitidine on   survival, 
Fenaux et al compared the efficacy of azacitidine to conven-
tional care regimens in patients with high-risk MDS.12–14 The 
358 patients were randomized 1:1 to receive azacitidine or 
a conventional care regimen that could include supportive 
care, low-dose cytarabine, or induction-type chemotherapy. 
Azacitidine was administered subcutaneously at 75 mg/m2 
daily for 7 consecutive days every 28 days for at least 
six cycles. A median of nine cycles of azacitidine was admi-
nistered (range 4–15 cycles). The primary endpoint in the 
  AZA-001study was overall survival. Patients treated with 
azacitidine had median overall survival of 24.5 months, 
while patients receiving conventional care had a median 
overall survival of 15.0 months. An analysis of the efficacy 
endpoints found significantly prolonged survival for patients 
in the azacitidine arm   compared with the best supportive care 
or low-dose cytarabine subgroups but not compared with 
the intensive chemotherapy subgroup, reflecting the small 
number of patients preselected to receive intensive chemo-
therapy. The estimated 2-year survival rates were 50.8% 
for patients   receiving azacitidine and 26.2% for patients 
  receiving conventional care; patients in the   azacitidine 
group also had higher rates of complete response (CR) 
(17%   versus 8%, P = 0.015) and partial response (PR) 
(12% versus 4%, P = 0.0094). Likewise, the median times 
to disease   progression, relapse after CR or PR, and death 
were   significantly longer in the azacitidine group than in the 
conventional care group (14.1 months versus 8.8 months, 
P = 0.047). The proportion of major erythroid   improvements 
(40% versus 11%, P , 0.0001) and major platelet improve-
ments (33% versus 14%, P = 0.0003) based in the Inter-
national Working Group 2000 criteria, were higher in the 
azacitidine group than in the conventional care group, but no 
significant difference in major neutrophil improvements was 
observed. The median duration of hematological response 
(CR, PR, and hematological improvements) was significantly 
longer in the azacitidine group than in the conventional care 
group (13.6 months versus 5.2 months, P = 0.0002). The 
rate of transformation to AML was lower in the azacitidine 
group than in the conventional care group, and the median 
time to AML transformation was 17.8 months in the azaciti-
dine group compared with 11.5 months in the conventional 
care group. In subgroup analysis, the time to progression 
for the azacitidine group was significantly lower than that of 
the best   supportive care subgroup but did not differ signifi-
cantly from that of either the low-dose cytarabine subgroup 
or the intensive chemotherapy subgroup. Results are sum-
marized in Tables 1 and 2. In summary, the   AZA-001study 
showed for the first time that a hypomethylating agent 
prolonged survival and decreased the risk of transformation 
to AML in patients with high-risk MDS compared with 
conventional therapies.
MDS patients with abnormalities in chromosome 7 (-7/
del(7q)) typically have poor outcomes with traditional treat-
ments. Follow up of the patients of the AZA-001 trial showed 
that patients in the azacitidine group with chromosome 7 abnor-
malities had a longer median overall survival time than those in 
the conventional care group (13.1 months   versus 4.6 months, 
Table 1 Phase III trials of azacitidine as a single agent
Study CALGB 9221 
No. (%) 
Updated CALGB 
No. (%)
AZA-001 
No. (%)
No. patients 99 99 179
CR 7 (7) 10 (10) 30 (17)
PR 16 (16) 1 (1) 21 (12)
Hi 37 (37) 36 (36) 87 (49)
OR 60 (60) 47 (47) 138 (78)
Abbreviations: CR, complete remission; PR, partial remission; Hi, hematological 
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P = 0.0017); for patients with   chromosome 7 abnormalities 
alone, the median overall survival time did not significantly 
differ between the two treatment groups (18.4 months versus 
10.3 months); however, in patients with -7/del(7q) as part 
of complex karyotype there was a significant difference 
between the median overall survival times of the azacitidine 
and conventional care groups (8.3 months versus 4.2 months, 
P = 0.0024). Therefore, azacitidine is the only treatment, aside 
from hematopoietic stem cell transplantation, to confer a 
demonstrable survival benefit in patients with MDS, including 
those with -7/del(7q) cytogenetic abnormality.12–14
Patients with high-risk MDS must undergo prolonged 
treatment with azacitidine to improve their outcomes, with 
a median of three cycles needed before the first evidence of 
response appears. In the AZA-001study, the survival advan-
tage was observed after three cycles of azacytidine com-
pared with the conventional care group, with separation of 
Kaplan–Meier survival curves. A total of 81% of patients had 
achieved an evidence of response by the sixth cycle of treat-
ment and an additional 9% of patients eventually responded 
to azacitidine by the ninth cycle. Furthermore, although the 
first response to azacitidine was a good response for over 
half the patients treated, a median of four additional cycles 
of azacitidine improved response in an additional 43% of the 
patients, suggesting that prolonged treatment with azacitidine 
may maximize the response to the agent.12,13,15
Alternative schedules and dosing
The standard dosing schedule of azacitidine for the treatment 
of MDS is 75 mg/m2 daily subcutaneously for 7 days in a 
28-day cycle (525 mg/m2 total). Because of the difficulty of 
continued administration for 7 days, in a randomized trial,16 
MDS patients were given azacitidine subcutaneously in one 
of three schedules every 4 weeks for six cycles: AZA 5-2-2 
(75 mg/m2 daily for 5 days, followed by 2 days of no treat-
ment, and then 75 mg/m2 daily for 2 days for a total dose of 
525 mg/m2 per cycle), AZA 5-2-5 (50 mg/m2 daily for 5 days, 
followed by 2 days of no treatment, and then 50 mg/m2 daily 
for 5 days for a total dose of 500 mg/m2 per cycle), or AZA 
5 (75 mg/m2 for 5 days for a total dose of 375 mg/m2). Most 
patients were FAB criteria-defined (had refractory anemia 
with ringed sideroblasts/chronic myelomonocytic leukemia 
with less than 5% bone marrow blasts, 63%) or refractory 
anemia with excess blasts (30%). Seventy-nine patients (52%) 
completed six or more treatments cycles. After six cycles of 
treatment, hematological improvement was reported in 44% 
(22 of 50), 45% (23 of 51), and 56% (28 of 50) of the patients 
in the AZA 5-2-2, AZA 5-2-5, and AZA 5 arms, respectively. 
Proportions of red blood cell transfusion-dependent patients 
who achieved transfusion independence were 50% (12 of 24), 
55% (12 of 22), and 64% (16 of 25) in the AZA 5-2-2, AZA 
5-2-5, and AZA 5 arms, respectively. More than one grade 
3 or 4 adverse event occurred in 84% (42 of 50), 77% (37 
of 51), and 58% (29 of 50) of patients the AZA 5-2-2, AZA 
5-2-5, and AZA 5 arms, respectively. All three alternative 
  dosing regimens produced hematological improvements, red 
blood cell transfusion independence, and safety responses 
consistent with the approved azacitidine regimen. However, 
results suggest that the AZA 5 dosing regimen may be better 
tolerated with a more convenient dosing schedule than the 
two alternative dosing regimens.
Azacitidine in transplantation
Immediate stem cell transplantation therapy has been rec-
ommended for patients with intermediate-2 and high-risk 
MDS according to the International Prognostic Scoring 
System because of their poor outcomes and short survival 
times.17 A frequent type of treatment failure after stem cell 
transplant is disease relapse, which is very difficult to man-
age. The graft-versus-leukemia effect can be magnified by 
weaning the patient from the immunosuppressive therapy 
and initiating a donor lymphocyte infusion, but this strategy 
is of very limited value, especially because of the risk of 
graft-versus-host disease.
Because induction chemotherapy is not suitable for some 
elderly patients or patients with other contraindications, and 
because modifications to conditioning regimens have not 
improved their tolerability, azacitidine has been considered 
Table  2  Results  of  the  AZA-001  trial  of  azacitidine  versus 
conventional care in patients with myelodysplastic syndromes13
Azacitidine 
N = [179]
Conventional 
care N = [179]
P
Median overall  
survival (mo)
24.5 15.0 P # 0.0001
2-year overall  
survival (%)
50.8 26.2 P , 0.0001
Median time to  
AML (mo)
17.8  11.5 P # 0.0001
Cytogenetic overall 
survival (mo)
-7/del (7q) 13.1 4.6 P = 0.0017
Response (%)
  CR 17 [30] 8 [14] P = 0.015
  PR 12 [21] 4 [7] P = 0.0094
  Stable disease 42 [75] 36 [65] P = 0.33
Notes: Definitions of hematological response and improvement were based on the 
international working Group 2000 criteria for MDS. 
Abbreviations: AML, acute myeloid leukemia; CR, complete remission; PR, partial 
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as an alternative. In a Nordic MDS study, 23 patients in 
CR after induction chemotherapy who were not eligible for 
allogenic transplantation received azacitidine at 60 mg/m2 
daily subcutaneously for 5 days in a 28-day cycle until 
relapse or unacceptable toxicity occurred. Unfortunately, 
the median duration of response was only 13.5 months 
(range 2–49 months) with just 30% of the cases remaining 
in CR beyond 20 months.18 A similar study by the Groupe 
Francophone des myélodysplasies (GFM) is currently under 
way. Patients with greater than 10% blasts in the bone   marrow, 
or greater than 5% if a nonmyeloablative transplantation is 
planned, may require treatment aimed at reducing the tumor 
burden to decrease the risk of relapse. Azacitidine has been 
observed to produce better responses in patients with unfa-
vorable cytogenetics.19 In a retrospective study the outcomes 
of 34 MDS patients who underwent stem cell transplanta-
tion were analyzed, 14 of whom had received azacitidine at 
standard doses before   transplantation. The Kaplan–Meier 
estimates for overall survival and progression-free sur-
vival between the two groups did not show clear evidence 
of a favorable outcome for either group, nor were there 
marked differences in toxic effects and other complications 
between the two groups. These results indicate that these 
two   treatment options are still valid approaches but deserve 
further analysis.20
As mentioned, outcomes for patients with early recur-
rence of AML are dismal. Maintenance therapy with azaciti-
dine may aid as an adjuvant for decreasing the recurrence rate 
after transplantation. Azacitidine appears to induce leukemic 
cell differentiation and to increase the expression of human 
leukemia antigen DR1 and several other tumor-associated 
  antigens, which can increase the graft-versus-leukemia 
effect.21–23 Moreover, in recent studies several mechanisms 
have been demonstrated through which azacitidine com-
promises the proliferation and activation of regulatory 
T   lymphocytes, mainly by blocking the cell cycle.24–26
In another study,27 40 patients with high-risk MDS or 
AML in CR without grade 3 or 4 graft-versus-host disease 
were assigned, on the basis of their toxicity profiles, to receive 
maintenance doses of azacitidine at 8 mg/m2, 16 mg/m2, or 
24 mg/m2 daily for 5 days, starting on day 42 after stem cell 
transplantation and given in 28-day cycles. Eleven patients 
relapsed; two of these relapses occurred during maintenance 
therapy. The day 30 and day 100 nonrelapse   mortality 
rates were 5% and 12%, respectively, with no increase 
in the graft-versus-host disease rates. Twelve patients 
received the 24 mg/m2 dose with no toxic effects for at least 
four cycles,   suggesting that higher doses and longer periods 
of   administration could be further investigated. In a later 
study including a higher dose of 32 mg/m2,   thrombocytopenia 
limited further dose escalation, though it was reversible. 
A randomized controlled trial of azacitidine for 1 year versus 
best standard care is ongoing.28
Few treatment options are available for patients whose dis-
ease relapses after transplantation. Moreover, less than 30% 
of patients with relapsed MDS achieve a complete response 
with donor lymphocyte infusion, which has a recurrence rate 
close to 33%.29 Because azacitidine is able to induce response 
in pretransplant MDS patients, it also has been proposed as a 
treatment for relapse after unrelated donor peripheral stem cell 
transplantation.30 This recommendation came from a study of 
six patients with high-risk myeloid malignancies and cytoge-
netic relapse after transplantation who received azacitidine 
at a minimum dose of 25 mg/m2 for 5 days. A reduction of 
cytogenetic abnormalities was observed in 83% of the patients 
shortly after one cycle of therapy, with one patient remaining 
in CR 4 months after the completion of therapy. The remain-
ing patients relapsed 30 days after the completion of therapy, 
reflecting activity but a short-lived response. Further investi-
gation may be necessary to evaluate azacitidine’s activity as 
pre-donor lymphocyte infusion regimen.
Azacitidine in elderly patients
As previously discussed, azacitidine was the first treatment 
to significantly extend overall survival times in patients with 
high-risk MDS. It is also known that the incidence of MDS 
increases with age, resulting in limited treatment options – 
particularly for fragile patients and those older than 75 years, 
who cannot adequately tolerate cytotoxic therapies. Therefore, 
an important goal of therapy is to reduce the   transfusion 
dependence and delay the progression of disease while 
maintaining a basically favorable toxicity profile. A subset 
analysis of the AZA-001 trial in patients older than 75 years 
demonstrated higher overall survival rates at 2 years in the 
azacitidine group (55%) than in the conventional care group 
(15%).31 Moreover, azacitidine generally was well tolerated in 
patients older than 75 years and produced transfusion indepen-
dence in 44% of the patients who received it, compared with 
22% in the conventional care group. Similar results have been 
reported elsewhere.32 It is of interest that most patients older 
than 75 years randomized to the   conventional care regimen 
group received basic support only,   suggesting that clinicians 
are generally unlikely to administer more   aggressive treat-
ments to elderly patients. Although these studies may have 
included a selected,   relatively fit   subpopulation of patients, 
the results of both studies clearly demonstrate azacitidine’s Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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better response rates compared with conventional care and 
its acceptable safety profile for elderly patients.
Azacitidine in lower-risk MDS
It is known that 90% of patients with an initial diagnosis of 
MDS present with anemia and eventually become transfu-
sion dependent. The erythropoiesis-stimulating agents, with 
or without granulocyte-colony stimulating factors, can be 
effectively used in the initial management in low-risk MDS to 
reduce the need for transfusions; however, some patients with 
lower-risk disease may need treatments other than growth 
factors. The best score to predict MDS natural history is the 
International Prognostic Scoring System, but this system has 
several limitations, the most important of which is the iden-
tification of patients who may face a poor prognosis despite 
having lower-risk disease (low and intermediate-1 risk). 
A new scoring system, the MDACC score, was developed 
at The University of Texas MD Anderson Cancer Center to 
provide insight into which patients may benefit from more 
aggressive treatment. This was done by dividing a subset 
of patients into three categories depending on cytogenetics, 
hemoglobin levels, thrombocytopenia, age, and number of 
blasts in the bone marrow.33
To date, few data have been made available regarding 
the specific use of azacitidine in patients with lower-risk 
disease. The CALGB 9221 trial included 44 patients with 
low-risk disease in its analysis. The overall response observed 
in patients with low-risk MDS receiving azacitidine was 
59% (9% CR, 18% PR, and 32% hematological improve-
ment), with an overall survival of 44 months compared with 
27 months for the control group. Recently, a multicenter 
prospective community-based study (AVIDA)34 reported 
a series of 52 transfusion-dependent patients. In total 42% 
achieved transfusion independence while on azacitidine; 
67% of the patients who achieved transfusion independence 
did so after the second cycle of treatment. A significant 
62% of patients were able to reach platelet transfusion 
independence; 88% of the patients who achieved platelet 
transfusion independence did so after the second treatment 
course, with minimal side effects. A more recent retrospective 
Italian study35 evaluated 74 patients with low-risk MDS who 
received azacitidine at 75 mg/m2 or 100 mg/m2 in monthly 
schedules   subcutaneously. The overall response in these 
patients was 45.0% (10.0% complete response, 9.5% partial 
response, and 20.3% hematological response). Hematological 
  improvements were not as strong as those reported in higher-
risk populations. We believe that the MDACC score could be 
used to better identify the subset of patients with lower-risk 
disease who would benefit from early therapeutic regimens, 
which may help improve their overall survival times. Further 
analyses are warranted.
Oral azacitidine
An oral formulation of azacitidine could facilitate dosing, 
reduce side effects, and favor compliance. It is postulated 
that oral formulations of the hypomethylating agents fail 
Diagnosis IPSS MDACC
MDS
Lower risk IPSS
Higher risk IPSS
MDACC category 1
MDACC category 2–3
Cytogenetics
Age
Performance status
Figure 1 Classification of myelodysplastic syndromes based on the MD Anderson Cancer Center scoring classification.
Abbreviations: iPSS, international Prognostic Scoring System; MDACC, MD Anderson Cancer Center scoring system; MDS, myelodysplastic syndromes.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
226
Vigil et al
because they undergo rapid catabolism by cytidine deami-
nase and hydrolysis in aqueous environments. A phase 0 pilot 
study demonstrated plasma concentrations of azacitidine 
that were comparable to those achieved by   subcutaneous 
injection.36 A subsequent phase I study of 40 patients 
receiving the first 75 mg/m2 dose of azacitidine subcutane-
ously and then escalating doses (from 120 mg to 600 mg) 
of azacitidine orally over the next 7 days   demonstrated 
that oral azacitidine was well tolerated with low toxicity.37 
The maximum tolerated dose was 480 mg, with grade 3 
and 4 diarrhea observed in two of the three patients in 
the 600 mg cohort. The plasma concentration range was 
5% to 35% for the first and 15% to 74% in the last group. 
Twenty-nine percent of the patients had a complete response 
and 43% had stable disease after six cycles of therapy. 
Nevertheless, the exposures for the oral dosing regimens 
were lower than the historical data for   subcutaneous dos-
ing, providing the rationale for an extended schedule and 
twice-daily dosing in a future trial.38
Azacitidine in combination therapy
The goals of combining azacitidine with other agents are to 
increase the response rates and to prolong the duration of 
response while maintaining low rates of toxic effects. Based 
on models of epigenetic biology and utilizing azacitidine’s 
synergistic effects, several combinations of azacitidine with 
histone deacetylase (HDAC) inhibitors have been assessed. 
The concept is based on the reactivation of suppressed anti-
cancer genes.39 Valproic acid is a short-chain fatty acid HDAC 
inhibitor with modest activity as a single agent, but it has 
shown activity in combination with other hypomethylating 
agents.40,41 The median overall survival for patients receiving 
valproic acid plus azacitidine was 14.4 months, and the 
  disease progressed in 32% of the patients. Other   investigators 
have sought to improve this result by looking to all-trans 
retinoic acid, a cell differentiation agent that releases co-
repressors and HDACs and induces the   expression of   target 
genes.42 This activity suggests the possibility that adding 
all-trans retinoic acid to the combination of azacitidine and 
valproic acid could potentiate the combination’s effects. Of 
the four patients with MDS receiving the three-drug combi-
nation, two achieved a complete response and the other two 
a bone marrow response.43 Another phase I study   combining 
azacitidine with the HDAC inhibitor MS-275, showed a 
44% overall response rate, with 7 of 13 patients with MDS 
achieving a response.44
MGCD0103 is a selective HDAC inhibitor that demon-
strated promising activity as a single agent in MDS patients. 
In a phase I/II study, patients with relapsed/refractory MDS 
or AML received a standard dose of subcutaneous   azacitidine 
plus MGCD0103 in escalating doses from 35 mg to 135 mg 
three times per week commencing on day five of azacitidine.45 
Eleven (30%) of the patients responded, with four achieving 
a complete response, five achieving an incomplete response, 
and two achieving a partial response. The maximum   tolerated 
dose of MGCD0103 was fixed at 90 mg because of severe 
nausea, vomiting, and dehydration at higher doses.   Additional 
combination trials with other broad and more specific HDAC 
inhibitors are underway.
Empiric combinations of drugs with demonstrated indi-
vidual activity have been evaluated in several other clinical 
trials. Thalidomide, an effective modulator of immune 
response with anti-angiogenic activity, was administered 
in escalating doses with a standard dose of azacitidine for 
MDACC score 1
MDACC score 2–3
Supportive care
High risk MDS
Hypomethylating agents
Highly intensive treatment
Hypomethylating agents
Clinical trials
Clinical trial
Figure 2 Treatment algorithms of myelodysplastic syndromes at MD Anderson Cancer Center.
Abbreviations: MDACC, MD Anderson Cancer Center scoring system; MDS, myelodysplastic syndromes.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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5 days.46 Of the 40 patients enrolled, 15% experienced a 
complete response and a hematological improvement was 
observed in 42%. In a phase I study with 18 patients, azaciti-
dine was tested in combination with lenalidomide, which had 
demonstrated activity in MDS patients with 5q chromosome 
abnormalities.47 The treatment regimen was well tolerated, 
and the overall response rate for the 17 evaluable patients was 
71%, with 41% of patients achieving a complete response. 
This combination was well tolerated, with a significant clini-
cal activity encouraging for further analysis. A clinical trial 
is planned in which patients will receive a 75-mg/m2 dose 
of azacitidine from days 1 through 5 and a 10-mg dose of 
lenalidomide from days 1 through 21.
Preliminary data from preclinical studies of the mecha-
nisms that may cause MDS have implicated tumor necrosis 
factor-α2 receptors. Therefore, a combination of etanercept, 
a tumor necrosis factor-α blocker, and azacitidine was 
  evaluated in a phase II study of 23 patients. Azacitidine was 
given in the standard 7-day dose, while etanercept was admin-
istered at 25 mg subcutaneously twice a week for 2 weeks in 
a 28-day cycle. It is notable that 14 patients responded, with 
28% achieving CR and 44% achieving PR.48
Targeting cell surface markers has also been studied for 
the treatment of MDS. CD33 is a surface marker known 
to be present in early hematopoietic stem cell precursors. 
Gemtuzumab ozogamicin, an antibody attached to a toxin 
that targets CD33-expressing cells, has produced good 
responses in hematological malignancies. Its combination 
with azacitidine has been assessed in early clinical trials in 
patients with refractory or relapsed AML or MDS.49 Median 
overall survival was 21 weeks, and 27% of patients achieved 
a complete response. Notably, 26% of patients with   refractory 
disease had a documented complete response, and the median 
overall survival was 40 weeks. A prospective clinical trial is 
underway.
Failure of treatment
Hypomethylating agents are currently the standard 
therapy for the treatment of MDS, but the prognosis 
after a failure of the treatment, although thought to be 
poor, has not been well documented. Recently, a single 
institution retrospective study of 87 patients, had deter-
mined an expected median survival of 4.3 months, with 
no difference in the outcome noted between patients 
who progressed to AML or who did not. An important 
validation of MDACC risk model was done, demonstrat-
ing the utility of the model for advice in prognosis and 
treatment alternatives.50
Safety
Azacitidine appears to be well tolerated, with the most com-
mon grade 3 or 4 events being peripheral blood cytopenias.6 
Injection site complications are the most common treatment-
related non-hematological complications in   subcutaneous 
azacitidine dosing, followed by nausea and vomiting. 
Although sometimes severe, myelosuppression is usually tran-
sient, with most patients recovering before their next treatment 
or usually managed with dosing delays (23%–29%).51
The highest proportion of adverse events occurs during 
the first two cycles, and the drug’s tolerability improves sub-
sequently. The infection rates were not statistically different 
when comparing with basic support (RR = 1.00 [95% CI: 0.81, 
1.22], P = 1.00]. The administration-related events such as 
nausea and vomiting occurred typically in the first week of 
drug delivery, resolved with antiemetics during the studies. 
The majority of injection site complications are typically mild 
erythema, and most improve after the application of warm or 
cold compresses to the affected area for a couple of hours.
This drug is mainly renally excreted (50%–85%), and 
some renal complications have been reported, although these 
are rare. These have included serum creatinine elevation, 
renal failure, renal acidosis, and death, and occurred more 
often when azacitidine was given in combinations with other 
drugs and at higher doses for non-MDS conditions.52 Azaciti-
dine has not been studied in patients with renal impairment 
and MDS. In patients with decreased levels of serum bicar-
bonate (, 20 mEq/L) or unexplained elevations of creatinine, 
dose reductions may be warranted. Caution should also be 
used in patients with hepatic impairment. Early studies asso-
ciated hepatic toxicity, including coma, with subcutaneous 
injections of azacitidine.6,53 All of these patients who became 
comatose had liver metastasis at the time of treatment. Based 
on these reports, azacitidine is contraindicated in patients 
with advanced hepatic tumors, and caution is needed when 
administering azacitidine to patients with other liver condi-
tions. Also unknown are the interactions between azacitidine 
and microsomal enzyme inhibitors or inducers. We are 
unaware of any current information regarding its effect on 
cytochrome P450 or other drug interactions.
Women of childbearing age should be warned of azaciti-
dine’s potential effects on the pregnancy and instructed not to 
breastfeed and to avoid pregnancy while receiving therapy. 
It is not known whether the drug is safe in children.54
Conclusion
Until recently, few treatments were available for MDS, and 
these yielded poor results. Azacitidine has risen as a keystone Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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in MDS treatment because it prolongs survival; however, 
responses are slow and short. It has been demonstrated that 
azacitidine has synergistic effects with other molecules, 
which potentiate azacitidine’s effects. More investigational 
clinical trials of azacitidine are underway, and more trials are 
needed to improve the clinical course of this disease.
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